Merged with Pherecydes in Sep 2023
ERYP - ERYTECH Pharma S.A.
NASDAQ
->
Healthcare
->
Biotechnology
Lyon,
France
Type: Equity
ERYP price evolution
ERYP
| (in millions $) | 31 Jan 2023 | 30 Oct 2022 | 30 Jul 2022 | 1 May 2022 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $38.79 | $53.34 | ||
| Short term investments | $0.71 | |||
| Net receivables | $2.53 | $5.47 | ||
| Inventory | ||||
| Total current assets | $42.63 | $62.12 | ||
| Long term investments | $0 | |||
| Property, plant & equipment | $2.98 | $3.65 | ||
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $45.81 | $65.99 | ||
| Current liabilities | ||||
| Accounts payable | $1.56 | $11.99 | ||
| Deferred revenue | ||||
| Short long term debt | $3.34 | $6.8 | ||
| Total current liabilities | $11.68 | $27.56 | ||
| Long term debt | $10.23 | $10.46 | ||
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $22.32 | $43.55 | ||
| Shareholders' equity | ||||
| Retained earnings | -$0.23 | -$30.92 | ||
| Other shareholder equity | -$28.36 | $1.28 | ||
| Total shareholder equity | $23.49 | $22.44 | ||
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $38.79 | $33.7 | $44.45 | $73.17 |
| Short term investments | $0.01 | $0.06 | $0.04 | |
| Net receivables | $2.53 | $5.09 | $4.33 | $5.82 |
| Inventory | $0.36 | |||
| Total current assets | $42.63 | $40.05 | $49.63 | $81.58 |
| Long term investments | $0 | $0.06 | $1.09 | $0.72 |
| Property, plant & equipment | $2.98 | $25.83 | $29.09 | $35.64 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $35.15 | $41.4 | ||
| Total investments | ||||
| Total assets | $45.81 | $66.77 | $80.4 | $118.55 |
| Current liabilities | ||||
| Accounts payable | $1.56 | $14.15 | $20.91 | $13.78 |
| Deferred revenue | ||||
| Short long term debt | $3.34 | $1.98 | $3.87 | $1.53 |
| Total current liabilities | $11.68 | $20 | $29.35 | $19.88 |
| Long term debt | $10.23 | $18.11 | $19.16 | $11.28 |
| Total noncurrent liabilities | $28 | $14.68 | ||
| Total debt | ||||
| Total liabilities | $22.32 | $43.92 | $53.86 | $32.99 |
| Shareholders' equity | ||||
| Retained earnings | -$0.23 | -$79.09 | -$97.92 | -$199.27 |
| Other shareholder equity | -$28.36 | $1.22 | $1.74 | $1.34 |
| Total shareholder equity | $23.49 | $22.84 | $26.54 | $85.56 |
| (in millions $) | 31 Dec 2022 | 30 Sep 2022 | 30 Jul 2022 | 1 May 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $5.22 | $0.47 | $25.3 | $0.54 |
| Cost of revenue | ||||
| Gross Profit | $5.22 | $0.47 | ||
| Operating activities | ||||
| Research & development | -$0.47 | $3.08 | ||
| Selling, general & administrative | $3.02 | $2.96 | ||
| Total operating expenses | $2.55 | $6.04 | $25.21 | $13.05 |
| Operating income | $2.68 | -$5.57 | ||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$3.32 | $0.1 | $3.74 | |
| Interest expense | -$3.97 | -$0.61 | $2.6 | $0.6 |
| Net income | ||||
| Net income | $5.94 | -$5.14 | -$1.02 | -$11.91 |
| Income (for common shares) | $5.94 | -$5.14 | ||
| (in millions $) | 31 Dec 2022 | 31 Jan 2022 | 30 Dec 2020 | 30 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $6.65 | $4.18 | $3.72 | $5.28 |
| Cost of revenue | ||||
| Gross Profit | $6.65 | $3.72 | $5.28 | |
| Operating activities | ||||
| Research & development | $19.91 | $57.58 | $52.19 | |
| Selling, general & administrative | $13.89 | $14.97 | $17.16 | |
| Total operating expenses | $33.79 | $60.7 | $72.55 | $69.36 |
| Operating income | -$27.15 | -$68.83 | -$64.07 | |
| Income from continuing operations | ||||
| EBIT | -$68.83 | -$64.07 | ||
| Income tax expense | $0.52 | $0 | -$0 | |
| Interest expense | -$0.32 | $3.28 | -$2.16 | -$0.49 |
| Net income | ||||
| Net income | -$0.23 | -$53.8 | -$73.3 | -$62.66 |
| Income (for common shares) | -$0.23 | -$73.3 | -$62.66 | |
| (in millions $) | 31 Jan 2023 | 30 Jul 2022 | 31 Dec 2021 | 30 Jun 2021 |
|---|---|---|---|---|
| Net income | -$25.85 | $45.35 | ||
| Operating activities | ||||
| Depreciation | $2.89 | -$2.5 | ||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$24.16 | $19.11 | ||
| Investing activities | ||||
| Capital expenditures | -$0.15 | $0.99 | ||
| Investments | ||||
| Total cash flows from investing | $38.13 | $37.95 | -$0.07 | $1.21 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $5.31 | $29.19 | ||
| Net borrowings | $5.58 | -$20.58 | ||
| Total cash flows from financing | -$1.77 | $1.99 | $10.65 | $8.61 |
| Effect of exchange rate | $0.49 | $0.4 | $0.95 | $1.69 |
| Change in cash and equivalents | $5.09 | $19.64 | -$12.63 | $30.61 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | -$0.23 | -$53.8 | -$73.3 | -$62.66 |
| Operating activities | ||||
| Depreciation | $2.9 | $5.38 | $4.99 | $4.22 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | -$31.76 | -$56.77 | -$51.72 | -$43.31 |
| Investing activities | ||||
| Capital expenditures | -$0.09 | -$0.3 | -$1.14 | -$20.12 |
| Investments | ||||
| Total cash flows from investing | $38.13 | -$0.34 | -$1.48 | -$19.84 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $34.63 | $0.13 | $0.05 | |
| Net borrowings | -$1.54 | $10.46 | $25.46 | -$1.72 |
| Total cash flows from financing | -$1.77 | $44.71 | $25.45 | $0.04 |
| Effect of exchange rate | $2.89 | $1.66 | -$0.98 | $1.91 |
| Change in cash and equivalents | $5.09 | -$10.75 | -$28.73 | -$61.2 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 31.02M |
| Revenue | $31.53M |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$12.13M |
| Revenue Q/Q | 173.30% |
| Revenue Y/Y | 514.10% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.67 |
| Cash/Share | 1.25 |
| EPS | -$0.39 |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 0.95 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 3.65 |
| Quick ratio | N/A |